KCNH4 and small cell lung carcinoma: BEC2 vaccination in the SCLC treatment paradigm, while yielding a long median relapse-free survival for SCLC patients who achieved complete remission in individual studies, the subsequent phase III clinical trials failed to confer a significant benefit in terms of OS and PFS.